Hong et al. examined the use of sotorasib (a KRAS p.G12C mutant inhibitor) in patients with advanced non-small cell lung cancer (NSCLC), CRC and other solid tumors and reported improved objective response rate (ORR) and disease control (defined as at least partial RR or stable disease) [39]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.